copper(2+)

Overview

copper(2+) (Cu²⁺), commonly called the cupric ion, is the divalent cation of the transition metal copper and the predominant oxidation state of copper in extracellular biological fluids. As an essential trace element, copper serves as a catalytic cofactor for metalloenzymes involved in mitochondrial respiration, antioxidant defense, iron mobilization, and connective tissue cross-linking. Because free ionic copper is toxic, its distribution is tightly controlled by membrane transporters, ATPase copper-transporting proteins, and intracellular copper chaperones, which keep the unbound cytosolic pool vanishingly small. glutathione and other thiols buffer the labile fraction. Disturbed copper handling has been linked to neurodegenerative conditions such as Alzheimer's disease, where Cu²⁺ binds amyloid beta (Aβ), as well as to cancer, insulin resistance, and cardiovascular disease.

The defining chemical property of Cu²⁺ is its redox activity: cycling between the cupric (Cu²⁺) and cuprous (Cu⁺) states allows it to react with hydrogen peroxide in Fenton-like chemistry, generating reactive oxygen species that damage lipids, proteins, and nucleic acids and impose oxidative stress. This same reactivity is exploited therapeutically. copper overload triggers cuproptosis, a copper-dependent form of cell death distinct from apoptosis and ferroptosis that proceeds through mitochondrial lipoylated-protein aggregation and depends on ferredoxin 1 (FDX1); related strategies deplete glutathione or engage the Nrf2/GPx4 axis and the cGAS-STING pathway to sensitize tumors and support cancer immunotherapy. In materials chemistry, Cu²⁺ acts as a coordinating node: it templates metal-organic frameworks and histidine-containing peptide metallogels used as drug carriers, and copper-based nanozymes display peroxidase-like catalytic activity that is harnessed for signal amplification in electrochemical biosensors. Cu²⁺ is likewise a common analytical target as an environmental heavy-metal contaminant, detected by CRISPR-Cas12a and nanomaterial platforms or removed by cellulose-based adsorbent hydrogels, and its antimicrobial oxidative activity is active against organisms including Staphylococcus aureus and Pseudomonas aeruginosa.

Recent Publications Summary (latest 30 papers)

Recent studies have used copper(2+) as a catalytic, coordination, or therapeutic component in biosensing platforms, nanomedicines, and environmental assays. In electrochemical and CRISPR-based sensors, Cu2+ was incorporated into a copper-imidazole nanozyme to enhance peroxidase-like activity for signal-amplified aptasensing of cardiac troponin I, while a separate CRISPR platform extended to copper-ion detection by swapping allosteric transcription factor modules 42455351Jul42393911Jul. A microfluidic surveillance system combined CRISPR-Cas12a with MOF-based bio-barcode technology for multiplex heavy-metal monitoring in wastewater, reporting a Cu2+ detection limit of 0.26 nM 42381600Jul. Other analytical formats used Cu2+ in coordination quenching or click-amplification schemes, including a DNA-antibody clamp sensor for CA242 and an explosive-copper-liposome strategy for ultrasensitive biomarker quantification in body fluids 42068271May41854094Mar.

A large cluster of publications focused on copper(2+)-enabled cancer therapy, especially cuproptosis, ferroptosis, and reactive oxygen species amplification. copper-based nanoassemblies, including copper-doped Prussian blue, CaO2-powered nanomotors, GE11/RGD-modified copper nanoassemblies, and layered double hydroxide nanoplatforms, were designed to release Cu2+ in the tumor microenvironment, deplete glutathione, disrupt mitochondrial function, and trigger cuproptosis or combined cuproptosis/ferroptosis 42142675May42126988May42044237Apr41830770Mar. Several studies paired Cu2+ with photothermal, photodynamic, or sonodynamic therapy to intensify oxidative stress and immune activation, including mitochondria-targeting nanodrugs, redox-imbalance amplifiers, and dual-ligand copper nanoassemblies that also activated the cGAS-STING pathway 42002062Apr41952381Apr42044237Apr. Other copper-centered anticancer systems included paeoniflorin-copper biocomplexes, copper-coordinated carbon dots, and copper-doped bioactive glass or metal-organic-polymer frameworks, all leveraging Cu2+ release for apoptosis, chemodynamic therapy, or combined chemo-dynamic and photothermal effects 41810719Mar42003487Apr42333417Jun.

copper(2+) also appeared in studies of antimicrobial therapy, wound healing, and drug reactivation. A copper-based core-satellite nanomedicine released Cu2+ in acidic infected wounds to generate hydroxyl radicals and achieve potent antibacterial activity while supporting cell migration and healing 42003695Apr. In diabetic drug-resistant infections, copper-coordinated nanoassemblies promoted bacterial cuproptosis-like death and wound repair 42054707Apr. Another study showed that Cu2+ salts could restore the antibacterial activity of tigecycline under light exposure by modulating its photodegradation pathway, with copper gluconate-tigecycline retaining efficacy in animal infection models 42215682May. copper(2+) was also used in adsorption and remediation materials for wastewater treatment, including cellulose-based hydrogels, covalent organic framework-enhanced hydrogels, and bacterial cellulose aerogels that removed Cu2+ alongside dyes and other heavy metals 42235769Jun42219096May42103132May.

Beyond materials and therapy, recent work examined copper(2+) in physiology, disease association, and copper homeostasis. A phase 2 trial evaluated tiomolibdate choline, a copper-binding agent, in Wilson disease 42155004May. In polycystic ovary syndrome, serum Cu levels and Cu/Zn ratios were associated with insulin resistance, body mass excess, and subclinical inflammation 42137979May. In biobanking research, long-term cryopreservation altered serum metallomic profiles, including copper, alongside proteomic changes 42348576Jun. Additional studies addressed copper detoxification and transport in plants, showing that nitrate reduced Cu uptake and translocation in Malus rootstock 42019077Apr, and a biopharmaceutical process study found that leachable copper from chromatography columns could catalyze oxidative antibody fragmentation during buffer exchange 42125798May.

What Changes, What Holds

1. copper(2+) is being used as a sensing and assay amplifier rather than only a target or contaminant
METHOD These studies mainly extend the analytical toolkit around Cu²⁺, showing that it can be built into nanozyme and CRISPR formats to improve signal generation and multiplex detection 42455351Jul42381600Jul. That does not alter the baseline chemistry or biology of copper(2+); it sharpens how the ion is measured and monitored in complex samples, including wastewater and biomarker assays.

2. copper(2+) remains a therapeutic redox trigger, but the new work broadens how deliberately it is deployed against tumors
REINFORCES The recent systems all lean on the same established logic in the Overview: Cu²⁺ release, glutathione depletion, mitochondrial injury, oxidative stress, and cuproptosis/ferroptosis to damage cancer cells 42142675May42044237Apr. Added photothermal, photodynamic, sonodynamic, and immune-activating components make the platforms more elaborate, but they do not displace the baseline account; they reinforce it and suggest the main uncertainty is translational durability rather than mechanism.

3. copper(2+) is also being repurposed for infected-wound killing and drug reactivation, expanding its antimicrobial role beyond the baseline
NEW DIRECTION The Overview already notes antimicrobial oxidative activity, but it does not specifically cover wound-healing nanomedicine or antibiotic reactivation. These studies show Cu²⁺ can be used to generate hydroxyl radicals in acidic infected tissue while supporting repair, and that copper salts can restore tigecycline activity under light 42003695Apr42215682May. That widens copper(2+) from a general antimicrobial agent to a context-sensitive therapeutic adjunct.

4. copper homeostasis is now being tied more directly to clinical monitoring, disease associations, and process-related oxidative damage
NEW DIRECTION Recent work adds a Wilson disease copper-binding therapy trial and a PCOS association with insulin resistance and inflammation, which extend the baseline’s disease links into new clinical settings rather than overturning them 42155004May42137979May. The cryopreservation and chromatography findings also matter because they show copper can shift during storage or catalyze unwanted protein oxidation, a practical concern the Overview does not address 42348576Jun42125798May.

Overview update candidates: copper-binding therapy in Wilson disease; serum copper/Cu-Zn associations with insulin resistance and inflammation; copper-related analytical and process artifacts in biobanking and biopharmaceutical workflows.